Apogee Therapeutics, Inc. (APGE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Core Insights - Apogee is preparing for a transformative year in 2026 with significant clinical readouts planned, including data points for their LEAP program and asthma studies [5] Group 1: Clinical Developments - In Q1 2026, Apogee will present data for their LEAP program (777) in atopic dermatitis (AD) and maintenance data, along with asthma data for the same compound [5] - Q2 2026 will feature Part B of Phase II trials, focusing on the dose response curve for 777 in AD [5] - The second half of 2026 will see a combination trial of IL-13 and OX40 ligand, with a Phase Ib trial ongoing against DUPI [5]